Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marco Borderi

Showing results (41-50 of 67) with videos related to

Pageof 7
Sort By:
Scandinavian Journal of Infectious Diseases|September 21, 2012
Incidence of renal toxicity in HIV-infected, antiretroviral-naïve patients starting tenofovir/emtricitabine associated with efavirenz, atazanavir/ritonavir, or lopinavir/ritonavirLeonardo Calza, Filippo Trapani, Caterina Salvadori, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|April 20, 2013
Prevalence of R5 strains in multi-treated HIV subjects and impact of new regimens including maraviroc in a selected group of patients with CCR5-tropic HIV-1 infectionIsabella Bon, Alberto Clò, Marco Borderi, et al.
Clinical and Experimental Nephrology|July 22, 2019
Prevalence of chronic kidney disease among HIV-1-infected patients receiving a combination antiretroviral therapyLeonardo Calza, Michele Sachs, Vincenzo Colangeli, et al.
Current HIV Research|November 5, 2015
Changes in Serum Markers of Inflammation and Endothelial Activation in HIV-Infected Antiretroviral Naive Patients Starting A Treatment with Abacavir-Lamivudine or Tenofovir-Emtricitabine Plus EfavirenzLeonardo Calza, Eleonora Magistrelli, Ilaria Danese, et al.
Infection|August 5, 2020
COVID-19 in patients with HIV-1 infection: a single-centre experience in northern ItalyLeonardo Calza, Isabella Bon, Marina Tadolini, et al.
Infectious Diseases (London, England)|December 7, 2017
Simplification to dual-therapy containing lamivudine and darunavir/ritonavir or atazanavir/ritonavir in HIV-infected patients on virologically suppressive antiretroviral therapyLeonardo Calza, Matteo Cafaggi, Vincenzo Colangeli, et al.
The Journal of Infectious Diseases|March 1, 2020
Calcaneal Quantitative Ultrasonography and Urinary Retinol-Binding Protein in Antiretroviral-Treated Patients With Human Immunodeficiency Virus in Uganda: A Pilot StudyCecilia Costa, Silvia Scabini, Arvind Kaimal, et al.
AIDS Reviews|June 26, 2018
A Comprehensive Development Agenda on Tenofovir Alafenamide in Clinical PracticeAntonio Di Biagio, Niccolò Riccardi, Stefano Rusconi, et al.
Infection|September 10, 2015
Heel quantitative ultrasound in HIV-infected patients: a cross-sectional studyMarilia Rita Pinzone, Daniela Castronuovo, Adriana Di Gregorio, et al.
Journal of Cellular Biochemistry|November 19, 2011
Analysis of the effects of HIV-1 Tat on the survival and differentiation of vessel wall-derived mesenchymal stem cellsDavide Gibellini, Anna Miserocchi, Pier Luigi Tazzari, et al.
Pageof 7

Showing results (41-50 of 67) with videos related to

Sort By:
Pageof 7
Scandinavian Journal of Infectious Diseases|September 21, 2012
Incidence of renal toxicity in HIV-infected, antiretroviral-naïve patients starting tenofovir/emtricitabine associated with efavirenz, atazanavir/ritonavir, or lopinavir/ritonavirLeonardo Calza, Filippo Trapani, Caterina Salvadori, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|April 20, 2013
Prevalence of R5 strains in multi-treated HIV subjects and impact of new regimens including maraviroc in a selected group of patients with CCR5-tropic HIV-1 infectionIsabella Bon, Alberto Clò, Marco Borderi, et al.
Clinical and Experimental Nephrology|July 22, 2019
Prevalence of chronic kidney disease among HIV-1-infected patients receiving a combination antiretroviral therapyLeonardo Calza, Michele Sachs, Vincenzo Colangeli, et al.
Current HIV Research|November 5, 2015
Changes in Serum Markers of Inflammation and Endothelial Activation in HIV-Infected Antiretroviral Naive Patients Starting A Treatment with Abacavir-Lamivudine or Tenofovir-Emtricitabine Plus EfavirenzLeonardo Calza, Eleonora Magistrelli, Ilaria Danese, et al.
Infection|August 5, 2020
COVID-19 in patients with HIV-1 infection: a single-centre experience in northern ItalyLeonardo Calza, Isabella Bon, Marina Tadolini, et al.
Infectious Diseases (London, England)|December 7, 2017
Simplification to dual-therapy containing lamivudine and darunavir/ritonavir or atazanavir/ritonavir in HIV-infected patients on virologically suppressive antiretroviral therapyLeonardo Calza, Matteo Cafaggi, Vincenzo Colangeli, et al.
The Journal of Infectious Diseases|March 1, 2020
Calcaneal Quantitative Ultrasonography and Urinary Retinol-Binding Protein in Antiretroviral-Treated Patients With Human Immunodeficiency Virus in Uganda: A Pilot StudyCecilia Costa, Silvia Scabini, Arvind Kaimal, et al.
AIDS Reviews|June 26, 2018
A Comprehensive Development Agenda on Tenofovir Alafenamide in Clinical PracticeAntonio Di Biagio, Niccolò Riccardi, Stefano Rusconi, et al.
Infection|September 10, 2015
Heel quantitative ultrasound in HIV-infected patients: a cross-sectional studyMarilia Rita Pinzone, Daniela Castronuovo, Adriana Di Gregorio, et al.
Journal of Cellular Biochemistry|November 19, 2011
Analysis of the effects of HIV-1 Tat on the survival and differentiation of vessel wall-derived mesenchymal stem cellsDavide Gibellini, Anna Miserocchi, Pier Luigi Tazzari, et al.
Pageof 7